BellRing Brands Investigation Overview
BFA is investigating whether BellRing violated the federal securities laws by making false and misleading statements to investors. Investors may be able to file a class action lawsuit to potentially recover losses.
If you lost money on your BellRing investment, you are encouraged to submit your information using the form on this page. You may also email ross@bfalaw.com or call 212.789.3619.
Why Is BellRing being Investigated for Securities Fraud?
BellRing is being investigated for securities fraud following significant stock drops resulting from potential violations of the federal securities laws. BellRing’s stock price declines caused significant losses to investors.
BellRing operates in the convenient nutrition category. The Company’s primary brands include Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders. During the relevant period, the Company stated that Premier Protein “hit an all-time high in household penetration” and that “demand remains strong.” The Company also stated that its growth was “strong in all channels,” driven by “distribution expansion, accelerating velocities and incremental promotional activity.”
In truth, the Company’s sales growth during the relevant period may have been driven by temporary trade inventory loading at several key retailers, not sustainable end-consumer demand.
Why did BellRing’s Stock Drop?
On May 5, 2025, after market hours, BellRing reported its fiscal Q2 2025 financial results and held an earnings call the following morning. During the earnings call, the Company revealed that starting in Q2 2023, “several key retailers lowered their weeks of supply on hand,” which would create a headwind to Q3 2025 growth. The Company announced it now expected Q3 net sales growth of “low single digits,” with Premier Protein as the main driver, and “all other[s] flat to down.” The Company also announced it was expanding promotions to boost sales and “offset [] third quarter reductions in retailer trade inventory levels.”
On this news, the price of BellRing stock dropped $13.96 per share, or more than 18%, from $77.34 per share on May 5, 2025, to $63.38 per share on May 6, 2025.
Then, on August 4, 2025, after market hours, BellRing reported its fiscal Q3 2025 financial results and held an earnings call the following morning. The Company announced that it was narrowing its fiscal 2025 net sales and adjusted EBITDA guidance. It also announced disappointing quarterly consumption of Premier Protein RTD Shakes, which had been expected to outpace shipments by a wider margin given previously announced retailer destocking, but instead came “more in line” with shipments.
On this news, the price of BellRing stock dropped $17.46 per share, or nearly 33%, from $53.64 per share on August 4, 2025, to $36.18 per share on August 5, 2025.
BellRing (BRBR) Stock Chart
NYSE online chart showing the BellRing (BRBR) stock drops following the May and August 2025 announcements.
How Do I Submit My Information?
If you lost money when BellRing securities dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.
You can also contact:
Ross Shikowitz
ross@bfalaw.com
212.789.3619
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of any class action lawsuit. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS.
BFA attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.
BFA’s notable successes include a recovery of over $900 million in value from Tesla Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
